Basal Cell Nevus Syndrome
Conditions
Keywords
Gorlin syndrome, Basal cell nevus syndrome BCNS, Nevoid basal cell carcinoma syndrome, Basal cell carcinoma, Hedgehog, Surgically eligible basal cell carcinomas, Patidegib
Brief summary
This is a global, multicenter, randomized, double-blind, stratified, vehicle-controlled study of the efficacy and safety of Patidegib Topical Gel, 2%, applied topically twice daily to the face of adult participants with Gorlin syndrome. Participants will be required to apply the investigational product for 12 months. The primary endpoint is a comparison between the two treatment arms of the number of new BCCs that develop over the 12 month period.
Detailed description
An open-label, extension safety and tolerability study is planned for at least 12 months duration following the end of this study. All participants who complete the Month 12 Exit Visit having demonstrated adequate compliance with application of the Investigational Product (IP) without major Protocol Deviations (PDs) during the study will be eligible for participation in the extension study. All participants will be contacted by phone approximately 30 days following the Exit or Discontinuation Visit to determine if the participant has experienced any new adverse events (AEs)/serious AEs (SAEs) since discontinuation/completion of study treatment.
Interventions
Patidegib Topical Gel, 2%
Patidegib Topical Gel, Vehicle
Sponsors
Sol-Gel Technologies, Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
As a double-blinded study, the Investigators, the site staff, Sponsor, and the Clinical Monitor(s) will be blinded to the treatment assigned to individual participants.
Intervention model description
Participants will be randomized 1:1 to receive Patidegib Topical Gel, 2%, or Vehicle (IP)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. The participant must be age at least 18 years of age at the Screening Visit. 2. The participant must provide written informed consent prior to any study procedures. 3. The participant must meet diagnostic criteria for the basal cell nevus (Gorlin) syndrome including major criterion #3a plus 1 additional major criterion or plus 2 additional minor criteria listed below. Major criteria: 1. \>2 histologically confirmed BCCs or 1 for participant under age 20. 2. Odontogenic keratocysts of the jaw confirmed histologically. 3. ≥3 palmar and/or plantar pits seen at the Screening Visit. 4. Bilamellar calcification of the falx cerebri present at less than 20 years of age. 5. Fused, bifid, or markedly splayed ribs. 6. First degree relative with Gorlin syndrome. 7. Patched protein 1 (PTCH1) mutation predicted to be of functional significance in normal tissue. Minor criteria: 1. Macrocephaly. 2. Congenital malformations including frontal bossing, cleft lip or palate, coarse face, moderate to severe hypertelorism. 3. Skeletal abnormalities detectable clinically: Sprengel deformity, marked pectus deformity, or marked finger syndactyly. 4. Skeletal abnormalities detectable radiographically: bridging of the sella turcica; vertebral abnormalities such as hemivertebrae, fusion or elongation of the vertebral bodies; modeling defects of the hands and feet; flame shaped lucencies of the hands or feet. 5. Ovarian fibroma. 6. Medulloblastoma (Modification of criteria of V Kimonis et al Am J Med Genet 69: 299-308, 1997). 4. The participant must have 10 (with at least 3 on the face) clinically typical BCCs present within 24 months prior to Randomization (Baseline/Day 1). Additionally, the subject must have at least 2 BCCs with longest diameter \<5 mm present on the face prior to Randomization (Baseline/Day 1). 5. The participant is willing to have blood collected to measure circulating drug levels. 6. The participant is willing to abstain from application of a non-study topical medication (prescription or over the counter) to facial skin for the duration of the trial except as prescribed by the Investigator. Moisturizers and emollients are allowed. Participant will be encouraged to use their preferred sunscreen with a sun protector factor (SPF) of at least 30 daily on all exposed skin sites. 7. If the participant is a woman of childbearing potential (WOCBP), she must be willing to use complete abstinence from sexual intercourse and/or she and her partner must be willing to use at least 2 highly-effective forms of birth control starting prior to Baseline, through the duration of the study, and for 12 months after last application of IP. 8. If the participant is a male with a female sex partner who is a WOCBP, the participant must be willing to use condoms, even after a vasectomy, starting prior to Baseline, through the duration of the study, and for at least 8 months after the last application of IP. 9. The participant is willing for all facial BCCs to be evaluated and treatment recommendations made only by the Investigator. 10. The participant is willing to forego treatment of facial BCCs with anything other than the study IP except when the Investigator believes that delay of treatment of a facial BCC potentially might compromise the health of the subject. During the trial the only allowed form of treatment is surgical. Non-facial BCCs may be removed at the discretion of the Investigator or Primary Skin Care Physician (PSCP).
Exclusion criteria
1. The subject has previously participated in a clinical trial evaluating patidegib topical gel. 2. The participant has used topical treatment to the face or systemic therapies that might interfere with the evaluation of the study IP. Among these are use of the following: 1. 5-fluorouracil, imiquimod, diclofenac, or Ingenol mebutate (except as topical treatment to discrete non-facial BCCs) systemically or topically to the skin within the 2 months prior to the Screening Visit. 2. Systemic chemotherapy within 1 year prior to the Screening Visit. 3. Known inhibitors of the Hedgehog signaling pathway (such as vismodegib, sonidegib, itraconazole) topically or systemically within 3 months prior to the Screening Visit. 4. Photodynamic therapy (PDT) except to localized non-facial, individual BCCs within 2 months prior to the Screening Visit. 3. The participant is known to have a hypersensitivity to any of the ingredients in the study medication formulation. 4. The participant is unable or unwilling to make a good faith effort to return to the study site for all study visits and tests. 5. The participant has uncontrolled systemic disease. 6. The participant has been treated for invasive cancer within the past 5 years excluding non-melanoma skin cancer, Stage I cervical cancer, ductal carcinoma in situ of the breast, or chronic lymphocytic leukemia (CLL) Stage 0. 7. The participant has current, recent (within five half-lives of the experimental drug or if half-life not known, within the past 6 months prior to the Screening Visit), or planned participation in an experimental drug study while enrolled in this study. 8. The participant is a WOCBP who is unwilling or unable to comply with pregnancy prevention measures. 9. The participant is pregnant or breastfeeding. 10. The participant has any condition or situation which, in the Investigator's opinion, may put the subject at significant risk, could confound the study results, or could interfere significantly with the subject's participation in the study. This may include a history of other skin conditions (such as severe facial eczema) or diseases, metabolic dysfunction, physical examination findings, or clinical laboratory findings giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or that might affect interpretation of the results of the study or render the participant at high risk from treatment complications.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of New BCCs Per Participant | Month 12 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of New Surgically Eligible BCCs (nSEBs) Per Participant | Month 12 | — |
| Percentage of Participants Developing >=2 Facial New BCCs | Month 12 | — |
| Percentage of Participants Developing >=1 Facial New BCCs | Month 12 | — |
| Number of New BCCs Per Participant | Month 9 | — |
| Change in Advanced Basal Cell Carcinoma Index (aBCCdex) Lesion Symptom Score Scale Score | Month 12 | The Advanced Basal Cell Carcinoma Index (aBCCdex) measures the impact of basal cell carcinoma on patients' quality of life. The index consists of several subscales, each subscale with its own range of scores for each question Lesion Symptoms Scale: Scores range from 1 to 7 and it includes 6 questions. Therefore the total score range is from 6 (minimum) to 42 (maximum), where a higher score correlates with a poorer quality of life. |
Countries
Belgium, Canada, Denmark, France, Germany, Italy, Netherlands, Spain, United Kingdom, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Patidegib Topical Gel, 2%, Participants will be randomized to receive Patidegib Topical Gel, 2%. The Patidegib Topical Gel, 2% will be dispensed to participants at each study visit and applied topically twice daily to the face.
Patidegib Topical Gel, 2%: Patidegib Topical Gel, 2% | 87 |
| Patidegib Topical Gel, Vehicle Participants will be randomized to receive Vehicle. The Patidegib Topical Gel, Vehicle will be dispensed to participants at each study visit and applied topically twice daily to the face.
Patidegib Topical Gel, Vehicle: Patidegib Topical Gel, Vehicle | 87 |
| Total | 174 |
Baseline characteristics
| Characteristic | Total | Patidegib Topical Gel, Vehicle | Patidegib Topical Gel, 2%, |
|---|---|---|---|
| Age, Continuous | 51.8 years STANDARD_DEVIATION 14.42 | 51.8 years STANDARD_DEVIATION 13.4 | 51.9 years STANDARD_DEVIATION 15.45 |
| BMI | 29.72 kg/m2 STANDARD_DEVIATION 5.938 | 29.58 kg/m2 STANDARD_DEVIATION 5.845 | 29.87 kg/m2 STANDARD_DEVIATION 6.062 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 8 Participants | 6 Participants | 2 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 151 Participants | 75 Participants | 76 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 5 Participants | 2 Participants | 3 Participants |
| Height | 176.18 cm STANDARD_DEVIATION 9.894 | 176.07 cm STANDARD_DEVIATION 10.421 | 176.30 cm STANDARD_DEVIATION 9.39 |
| Number of BCCs excluding SEBs at Baseline | 9.9 Number of BCCs STANDARD_DEVIATION 8.67 | 10.4 Number of BCCs STANDARD_DEVIATION 8.85 | 9.5 Number of BCCs STANDARD_DEVIATION 8.52 |
| Number of BCCs including SEBs at Baseline | 14.7 Number of BCCs STANDARD_DEVIATION 11.54 | 15.4 Number of BCCs STANDARD_DEVIATION 11.89 | 13.9 Number of BCCs STANDARD_DEVIATION 11.2 |
| Number of SEBs (surgically eligible basal cell carcinoma) at Baseline | 4.7 Numberof SEBs STANDARD_DEVIATION 6.45 | 5.0 Numberof SEBs STANDARD_DEVIATION 6.68 | 4.4 Numberof SEBs STANDARD_DEVIATION 6.25 |
| Previous Hedgehog Inhibitor therapy No | 106 participants | 54 participants | 52 participants |
| Previous Hedgehog Inhibitor therapy Yes | 68 participants | 33 participants | 35 participants |
| Race (NIH/OMB) American Indian or Alaska Native | 2 Participants | 2 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 2 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 5 Participants | 3 Participants | 2 Participants |
| Race (NIH/OMB) White | 157 Participants | 78 Participants | 79 Participants |
| Sex: Female, Male Female | 97 Participants | 49 Participants | 48 Participants |
| Sex: Female, Male Male | 77 Participants | 38 Participants | 39 Participants |
| Time since Diagnosis of BCNS (basal cell nevus syndrome) | 27.03 years STANDARD_DEVIATION 16.668 | 25.82 years STANDARD_DEVIATION 16.379 | 28.24 years STANDARD_DEVIATION 16.96 |
| Weight | 92.41 kg STANDARD_DEVIATION 21.447 | 91.75 kg STANDARD_DEVIATION 20.101 | 93.06 kg STANDARD_DEVIATION 22.812 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 87 | 0 / 87 |
| other Total, other adverse events | 47 / 87 | 65 / 87 |
| serious Total, serious adverse events | 5 / 87 | 7 / 87 |
Outcome results
Primary
Number of New BCCs Per Participant
Time frame: Month 12
Population: The number of BCCs per subject by Month 12 summarized subjects with BCC assessments within the Month 12 analysis window.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Patidegib Topical Gel, 2%, | Number of New BCCs Per Participant | 2.84 New basal cell carcinomas | Standard Deviation 3.39 |
| Patidegib Topical Gel, Vehicle | Number of New BCCs Per Participant | 4.03 New basal cell carcinomas | Standard Deviation 4.76 |
Secondary
Change in Advanced Basal Cell Carcinoma Index (aBCCdex) Lesion Symptom Score Scale Score
The Advanced Basal Cell Carcinoma Index (aBCCdex) measures the impact of basal cell carcinoma on patients' quality of life. The index consists of several subscales, each subscale with its own range of scores for each question Lesion Symptoms Scale: Scores range from 1 to 7 and it includes 6 questions. Therefore the total score range is from 6 (minimum) to 42 (maximum), where a higher score correlates with a poorer quality of life.
Time frame: Month 12
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Patidegib Topical Gel, 2%, | Change in Advanced Basal Cell Carcinoma Index (aBCCdex) Lesion Symptom Score Scale Score | 11.49 score on a scale | Standard Deviation 18.365 |
| Patidegib Topical Gel, Vehicle | Change in Advanced Basal Cell Carcinoma Index (aBCCdex) Lesion Symptom Score Scale Score | 15.54 score on a scale | Standard Deviation 21.002 |
Secondary
Number of New BCCs Per Participant
Time frame: Month 6
Population: subjects with no postbaseline data were excluded from the analysis
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Patidegib Topical Gel, 2%, | Number of New BCCs Per Participant | 1.68 New basal cell carcinomas | Standard Deviation 2.82 |
| Patidegib Topical Gel, Vehicle | Number of New BCCs Per Participant | 2.12 New basal cell carcinomas | Standard Deviation 2.96 |
Secondary
Number of New BCCs Per Participant
Time frame: Month 9
Population: subjects with no postbaseline data were excluded from the analysis
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Patidegib Topical Gel, 2%, | Number of New BCCs Per Participant | 2.46 New basal cell carcinomas | Standard Deviation 3.42 |
| Patidegib Topical Gel, Vehicle | Number of New BCCs Per Participant | 3.15 New basal cell carcinomas | Standard Deviation 3.94 |
Secondary
Number of New Surgically Eligible BCCs (nSEBs) Per Participant
Time frame: Month 12
Population: The number of nSEBs per subject by Month 12 summarizes subjects with BCC assessments within the Month 12 analysis window.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Patidegib Topical Gel, 2%, | Number of New Surgically Eligible BCCs (nSEBs) Per Participant | 0.71 New basal cell carcinomas | Standard Deviation 1.28 |
| Patidegib Topical Gel, Vehicle | Number of New Surgically Eligible BCCs (nSEBs) Per Participant | 0.91 New basal cell carcinomas | Standard Deviation 1.61 |
Secondary
Percentage of Participants Developing >=1 Facial New BCCs
Time frame: Month 12
Population: subjects with no postbaseline data were excluded from the analysis
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Patidegib Topical Gel, 2%, | Percentage of Participants Developing >=1 Facial New BCCs | 56 Participants |
| Patidegib Topical Gel, Vehicle | Percentage of Participants Developing >=1 Facial New BCCs | 65 Participants |
Secondary
Percentage of Participants Developing >=2 Facial New BCCs
Time frame: Month 12
Population: subjects with no postbaseline data were excluded from the analysis
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Patidegib Topical Gel, 2%, | Percentage of Participants Developing >=2 Facial New BCCs | 45 Participants |
| Patidegib Topical Gel, Vehicle | Percentage of Participants Developing >=2 Facial New BCCs | 55 Participants |